Dergiler / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 1

Natriuretic Peptides in Clinical Practice

Sayfa
1–40
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this article, natriuretic peptides have been reviewed fortheir updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of variousclinical conditions have been addressed in the form of expert opinion based on the available data in the literature. (Anatol J Cardiol 2019: 21Suppl 1; 1-40)

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Natriuretic peptides have long been introduced into clinical practice.
📊
Temel Bulgular & Veri:These biomarkers have certainly been shown to provide useful informationin the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy.
💡
Sonuç & Katkı:In this article, natriuretic peptides have been reviewed fortheir updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of variousclinical conditions have been addressed in the form of expert opinion based on the available data in the literature. (Anatol J Cardiol 2019: 21Suppl 1; 1-40)
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful informationin the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although,there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number ofcandidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Recent heartfailure guidelines recognize natriuretic peptides as an essential tool in the new diagnostic and therapeutic algorithms. Furthermore, natriureticpeptides are not only used in the diagnosis or prognosis of heart failure, but also these biomarkers are referred to have some potential role inprimary prevention, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, pulmonary arterialhypertension, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this article, natriuretic peptides have been reviewed fortheir updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of variousclinical conditions have been addressed in the form of expert opinion based on the available data in the literature. (Anatol J Cardiol 2019: 21Suppl 1; 1-40)

🔖

Bu Makaleye Atıf Yap

ÇAVUŞOĞLU, Y., ALPER, A. T., ALTAY, H., ÇELİK, A., DEMİRKAN, B., GÜVENÇ, T. S., KÜÇÜKOĞLU, M. S., NALBANTGİL, S., ÖZDEMİR, M., ÖZİN, B., SAYIN, T., YILDIRIMTÜRK, Ö., YILMAZ, M. B., ZORKUN, C. (2019). Natriuretic Peptides in Clinical Practice. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 1, 1–40. https://ajindex.com/articles/365720

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 2013; 128: e240-327
  2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129-200
  3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol 2017; 70: 776-803
  4. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17–29
  5. Suga S, Itoh H, Komatsu Y, Ogawa Y, Hama N, Yoshimasa T, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells–evidence for CNP as a novel autocrine/ paracrine regulator from endothelial cells. Endocrinology 1993; 133: 3038–41
  6. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008; 1: 258-64
  7. Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrügg HR, Bartunek J, et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 2002; 105: 286–9
  8. Volpe M, DeLuca N, Atlas SA, Camargo MJ, Indolfi C, Lembo G, et al. Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients. Circulation 1988; 77: 997–1002
  9. Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM. Regional clearance of amino-terminal pro-brain natri- uretic peptide from human plasma. Eur J Heart Fail 2009; 11: 832–9
  10. Van Kimmenade RR, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro- B-type natriuretic peptide: a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009; 53: 884–90
  11. O’Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail 2005; 11(Suppl): S9–S1